Abstract: Peripheral blood lymphocytes (PBL) genetically modiWed to express T cell receptors (TCR) speciWc to known melanoma antigens, such as melanoma antigen recognized by T cells-1 (MART-1), and gp100 can elicit objective tumor regression when administered to patients with metastatic melanoma. It has also been demonstrated that modiWcations within the constant regions of a fully human TCR can enhance surface expression and stability without altering antigen speciWcity. In this study, we evaluated the substitution of murine constant regions for their human counterpart within the DMF5 MART-1-speciWc TCR. Unlike previous studies, all modiWed TCRs were inserted into retroviral vectors and analyzed for expression and function following a clinical transduction protocol. PBL were transduced with retroviral supernatant generated from stable packaging lines encoding melanoma-speciWc TCRs. This protocol resulted in high levels of antigen-speciWc T cells without the need for additional peptide stimulation and selection. Both the human and murinized TCR eYciently transduced PBL; however, the murinized TCR exhibited signiWcantly higher tetramer binding, mean Xuorescence intensity, as well as, increased in vitro eVector function following our clinical transduction and expansion protocol. Additional TCR modiWcations including insertion of a second disulWde bond or the linker modiWcations evaluated herein did not signiWcantly enhance TCR expression or subsequent in vitro eVector function. We conclude that the substitution of a human constant region with a murine constant region was suYcient to increase receptor expression and tetramer binding as well as antitumor activity of the DMF5 TCR and could be a tool to augment other antigen-speciWc TCR.
Introduction
Currently patients with metastatic melanoma have few curative options for therapy, as standard chemotherapy typically induces only transient beneWcial responses. Immunotherapy in the form of high-dose interleukin-2 (IL-2) can induce durable complete responses, but only in a small percentage of patients [1, 2] . Adoptive cell transfer (ACT) with autologous tumor inWltrating lymphocytes (TIL) has shown promise in phases I and II clinical trials, obtaining response rates of 49-72%, with many durable long-term survivors [3] [4] [5] . However, there are patients for whom TIL ACT is not a viable option: those without tumors that are easily resectable; those from whom TIL cannot be successfully cultured and expanded in vitro; and those whose TIL do not exhibit robust, speciWc eVector function. As an alternative to TIL ACT, we and others have successfully redirected non-reactive autologous peripheral blood lymphocytes (PBL) using T cell receptor (TCR) gene transfer to mediate antigen-speciWc tumor reactivity [6] [7] [8] [9] [10] . In a clinical trial, Morgan et al. [11] reported that a MART-1-speciWc TCR (DMF4), isolated and cloned from the TIL of a responding patient, resulted in a 13% objective response rate when introduced into non-reactive PBL from diVerent melanoma patients via retroviral transduction. In a separate, but related eVort, a high avidity TCR (DMF5) was cloned that also recognized MART-1, and when expressed in patient PBL conferred enhanced tetramer binding and functional activity as measured by interferon-(IFN ) release and cytotoxicity, and when evaluated in a phase II trial, the response rate was 30% by RECIST criteria [12, 13] . These data suggest that increased TCR avidity may enhance tumor recognition and provide a more eVective therapy; however, with an objective response rate below that of TIL therapy, additional improvements to ACT using genetically modiWed T cells are needed.
Several investigators have described methods for improving the surface expression and eVector function of transduced TCR by introducing a variety of genetic modiWcations, such as addition of murine sequences and cysteine substitutions into the coding regions of the human TCR -and -chain constant regions [14] [15] [16] [17] [18] . It was reported that replacement of the entire human constant region or select residues of this region with its murine counterpart resulted in enhanced antitumor activity and improved pairing between and chains of the exogenous TCR [15, 19] . In addition, modiWcations to introduce a second disulWde bond within the TCR constant region also resulted in enhanced antitumor activity presumably due to improved pairing [16] . However, the bulk of the published literature evaluates TCR function following RNA electroporation or retroviral co-transduction with individual vectors encoding the TCR and chains, respectively. Both methods result in relatively low levels of TCR expression making it diYcult to evaluate diVerences attributable to these receptor modiWcations. Recently, PBL were co-transduced with separate vectors encoding the human TCR and chains to generate a TCR directed against Wilms tumor antigen 1 (WT-1) [17] . The WT-1 TCR was then modiWed to improve pairing between the TCR and chains by either the addition of a cysteine residue to create a second disulWde bond or replacement of the human constant region with its' murine counterpart. Based on tetramer staining, the proportion of tetramer-positive T cells was low for all the WT-1 TCR tested, therefore, repeated antigen-speciWc peptide stimulation was required to increase the number of antigen-speciWc T cells. Importantly, following multiple rounds of peptide stimulation, neither the addition of a second disulWde bond within the constant region of the WT-1 wild-type TCR nor replacement of the human constant region with that of murine origin was found to confer improved function on these cells. Interestingly, only T cells transduced with TCRs modiWed to improve pairing were able to bind signiWcant levels of WT-1 tetramer following peptide stimulation. However, while the wild-type TCR could not eYciently bind tetramer based on FACS analysis, it was functionally equivalent to the modiWed TCR populations as measured by IFN release and cytotoxicity. These Wndings suggest that tetramer binding and TCR avidity or antitumor reactivity are not directly correlated implying that TCR modiWcations to improve pairing can enhance tetramer binding, but may not confer a functional advantage to the modiWed T cells.
Based on these Wndings, the series of experiments described herein were carried out to evaluate the eVects of modiWcation of the constant regions of the DMF5 HLA-A2-restricted MART-1-speciWc TCR. Using clinical grade, hightiter retroviral supernatant generated by stable packaging clones, TCR transductions yielded a high proportion (typically >50%) of antigen-speciWc tetramer-positive T cells, abrogating the need for additional peptide stimulation [9, 20, 21] . To directly compare diVerences between TCR expression and function, wild type and modiWed TCR were transduced into the same patient PBL and evaluated prior to and following our clinical rapid expansion protocol (REP) which involves non-speciWc TCR activation with a soluble anti-CD3 antibody and the use of irradiated peripheral blood monocyte (PBMC) feeders [22] . The addition of a cysteine residue to promote formation of a second disulWde bond, the substitution of a murine constant region and the introduction of an optimized linker sequence between the and chain coding regions were each evaluated for their ability to enhance the antitumor activity of gene modiWed T cells [23] . Under REP conditions, where the majority of TCR-transduced PBL are tetramer positive, we found that a chimeric murinehuman TCR conferred enhanced TCR expression and antitumor reactivity in comparison to the wild-type TCR.
Materials and methods

Patient peripheral blood mononuclear cells and cell lines
Melanoma cell lines HLA-A2 + /MART-1 + (526, 624, and 624.38) and HLA-A2 ¡ (888 and 938) were isolated from surgically resected metastases as previously described [24] and were cultured in R10 medium consisting of RPMI 1640 (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT). All peripheral blood mononuclear cells and lymphocytes used for transduction and as feeder cells were obtained from aphereses of Surgery Branch, NCI patients on IRB-approved protocols and cultured in AIM-V medium (Invitrogen, Carlsbad, CA) supplemented with 5% human AB serum (Valley Biomedical, Winchester, VA), -mercaptoethanol, non-essential amino acids, HEPES and L-glutamine (Invitrogen, Carlsbad, CA).
DMF5 vector modiWcations
To create the Mur-F5-cys, plasmid DNA (pMSGV1-F5 M-A2aB) encoding the Mur-F5 retroviral vector was modiWed using PCR-based site-directed mutagenesis (Stratagene, La Jolla, CA). The chain was ampliWed using a 5Ј-speciWc primer, GGAACGTTCATCACTGACAAATGCGTGCTG GACATGAAAGCTA and 3Ј-cysrev primer, TAGC TTTCATGTCCAGCACGCATTTGTCAGTGATGAAC GTTCC. The -chain was ampliWed using a 5Ј-speciWc primer, GGGGTCCACAGTGGGGTCTGCACGGACCCT CAGGCCTACA and 3Ј-cysrev primer, TGTAGGCCTGA GGGTCCGTGCAGACCCCACTGTGGACCTCC (mutated bases are underlined). Insertion of an optimized linker sequence between the and chains of Mur-F5 and Mur-F5-cys was done using two-step overlapping PCR using pMSGV1-F5M-A2aB and pGEM-F5MAcys and pGEMF5MBcys as templates, respectively. Initially, the chains were ampliWed with a 5Ј-speciWc primer engineered to add a PciI restriction enzyme cleavage site 5Ј to the start codon, CCCCACATGTATGGAAATCCTTGGAGTTTTAC and a 3Ј-speciWc primer engineered to add the Wrst 60 bp of the optimized linker sequence 3Ј to the constant region coding sequence, CCGGCCTGCTTCAGCAGGCTGAAGTTGGT GGCTCCGGATCCGGACCGCTTGGCCCGTCAACTGG ACCACAGCCTCAGCGT. The -chains were ampliWed with a 5Ј-speciWc primer engineered to add the terminal 60 bp of the optimized linker sequence 5Ј to the start codon, CCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGAC GTGGAGGAGAACCCCGGCCCCATGAGAATCAGGC TCCTGTGCTGT and a 3Ј-speciWc primer engineered to add a SalI restriction site 3Ј to the constant region coding sequence, CCCCGTCGACTCATGAATTCTTTCTTTTGA CCATAG. The resulting overlap of 20 bp centrally located in the linker sequence allowed a second ampliWcation with the and PCR products, using the 5Ј PciI primer and 3ЈSalI primer described above. Directional cloning was performed using PciI and SalI digest of the new constructs, compatible with NcoI and XhoI digest of an MSGV1 backbone. All PCR products were gel puriWed (Qiagen, Valencia, CA) and Wnal constructs were fully sequenced for veriWcation (Macrogen, Rockville, MD, USA). 293T cells were transiently transfected and retroviral supernatant was harvested after 48 h.
Retroviral supernatant
Clinical grade gamma-retroviral vector supernatant encoding the DMF5 TCR (WT-F5) was produced at the Indiana University Vector Production Facility (Indianapolis, IN). Clinical grade retroviral supernatant encoding the murinized DMF5 receptor (Mur-F5) was produced at the Surgery Branch Vector Production Facility (NCI, Bethesda, MD). BrieXy, a human ecotropic cell line, Phoenix ECO (kindly provided by Dr. Gary Nolan, Stanford University, Stanford, CA), was transfected with WT-or Mur-F5 plasmid in the presence of lipofectamine 2000 (Invitrogen, Carlsbad, CA). The transiently generated retroviral supernatant was used to transduce the PG13 (ATCC CRL-10686) gibbon ape leukemia virus packaging cell line. High-titer clones were identiWed by RNA dot blot, and following PBL transduction, cytokine release assays were used to select the Wnal packaging clones. The selected packaging clones were then used to generate retroviral vector supernatant as described previously with only slight modiWcations [20] . BrieXy, following supernatant harvest, the product was clariWed by "modiWed" step-Wltration in which the 20-m Wlter was omitted from the clariWcation process. For transduction experiments, supernatant was diluted with D10 medium consisting of high-glucose (4.5 g/L), Dulbecco's modiWed essential medium (DMEM, Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS, Hyclone, Logan, UT) and a Wnal concentration of 6 mM glutamine (Invitrogen, Carlsbad, CA).
PBL transduction
For virus titer determinations, PBL (2 £ 10 6 cell/mL) were stimulated with IL-2 (300 IU/mL) and OKT3 (50 ng/mL) on Day 0. Non-tissue culture treated 6-well plates were coated with retronectin (Takara Bio, Otsu, Shiga, Japan) at 10 g/mL, 2 mL/well on day 1 and stored overnight at 4°C. Serial dilutions of vector supernatant (4 mL/well, diluted with D10) were applied to plates on day 2 followed by centrifugation at 2,000£g for 2 h at 32°C. Half the volume was aspirated and PBL were added (0.25-0.5 £ 10 6 cell/mL, 4 mL/well), centrifuged for 10 min at 1,000£g followed by incubation at 37°C/5% CO 2 . Vector titers were calculated as follows: [(percentage of tetramer-positive cells £ total cell number £ dilution factor)]/supernatant volume. For the clinical transduction protocol, a second transduction on day 3 was performed as described above. Cells were maintained in culture at 0.7-1.0 £ 10 6 cell/mL. After harvest of one time stimulated cells for testing (S1d8-11), cells were rapidly expanded (REP) in the presence of soluble OKT3 (300 IU/mL), IL-2 (6,000 IU/mL) and irradiated feeders as previously described [22] . After day 5 of REP, cells were maintained in culture at 0.7-1.0 £ 10 6 cell/mL until harvested for testing on days 7-10 (R2d7-10).
FACS analysis
Receptor expression was analyzed using PE-conjugated HLA*A201/MART-1:27-35L peptide tetramer (BeckmanCoulter, San Jose, CA) in combination with APC-, PE-Cy7-, and APC-Cy7-conjugated antibodies directed at human CD3, CD4 and/or CD8 (BD Biosciences, San Jose, CA). Phenotype analysis was performed as above with the addition of antibodies directed at CD62L, CD45RO, CD27, CD69 (all APC-conjugated) and CD45RA, CCR7, CD28, and CD70 (FITC-conjugated). (BD Biosciences, San Jose, CA; except CCR7, Ebioscience, San Diego, CA). Isotype controls followed manufacturer's recommendations. ImmunoXuorescence analyzed as relative log Xuorescence of live cells was measured using a FACSCantoII Xow cytometer (Becton-Dickinson, San Jose, CA). Cells were stained in FACS buVer containing PBS, 0.5% bovine serum albumin, and 0.02% sodium azide.
Cytokine release assays TCR-transduced eVector cells (1 £ 10 5 ) and melanoma cell lines (1 £ 10 5 ) were placed in overnight co-culture (200 L) at 37°C/5% CO 2 . Supernatants were harvested for enzyme-linked immunosorbent assay (ELISA) to detect IFN (ThermoScientiWc, Waltham, MA). IL-2 assays were carried out as described above with the addition of -IL-2R monoclonal antibody at 5 g/mL. Enzyme-linked immunosorbent assay (ELISA) was performed for presence of IL-2 (R&D Systems, Minneapolis, MN). 51 Cr release assay
The ability of TCR-transduced PBL to lyse targets was measured using a 51 Cr release assay as described [12] . BrieXy, decreasing ratios of eVector and 51 Cr-labeled target cells (E:T) were co-incubated in R10 medium in 96-well plates for 4 h at 37°C. Percent lysis was measured by the 51 Cr release into the medium: percentage lysis = (sample release ¡ minimum release)/(maximum release ¡ minimum release) £ 100. Duplicate samples were averaged. SpeciWcity controls include untransduced (UT) S1 and R2 PBL, as well as, TCR-transduced PBL targeting mel624 (HLA-A2 + /MART-1 + ) and mel938 (HLA-A2 ¡ ) target cell lines.
Statistical analysis
The results of cytokine secretion were compared using a paired Student's t test. P values are two-tailed and indicated in the Wgures. The results of TCR modiWcations were compared using a one-way analysis of variance.
Results
A murine-human hybrid MART-1 speciWc TCR enhanced receptor expression in TCR-transduced human PBL A retrovirally encoded TCR was created in which the original human constant regions of the MART-1 speciWc DMF5 TCR isolated from a patient's TIL (referred to as WT-F5) were replaced by mouse sequences to generate a hybrid, murinized TCR (referred to as Mur-F5, Fig. 1 ). Plasmids encoding each receptor were used to generate stable packaging clones and clinical grade retroviral supernatant was used for TCR transduction of PBL. The titers for both WT-F5 and Mur-F5 were nearly identical, 1.46 § 0.22 £ 10 6 and 1.52 § 0.16 £ 10 6 transducing units (TU)/mL, respectively. PBL transductions consisted of spinoculation on two consecutive days with cells maintained in culture for approximately one additional week before undergoing a REP. Cells sampled prior to the REP were designated S1, denoting a stimulation and one exposure to OKT3; cells sampled after expansion were designated R2, denoting a REP and a second exposure to OKT3. To prevent assay variability in pairwise comparisons, all relevant samples for a single patient (untransduced, S1 WT-F5, S1 Mur-F5, R2 WT-F5, and R2 Mur-F5) were analyzed in the same experiment.
After stimulation and transduction with either the WT-F5 or Mur-F5 TCR, Mur-F5-transduced PBL yielded a signiWcantly higher percentage of T cells capable of binding MART-1-speciWc tetramer, a surrogate for TCR expression and transduction eYciency. In a representative experiment, PBL transduced with the Mur-F5 TCR bound higher levels of tetramer as compared to WT-F5, 74 and 57%, respectively (Fig. 2a) . In addition, the tetramer positive, Mur-F5 transduced cells had a visibly higher mean Xuorescence intensity as compared to WT-F5 [mean Xuorescence intensity (MFI), 1372 and 521, respectively, Fig. 2a ] indicating increased expression of the Mur-F5 TCR on a per-cell basis. After a REP, the Mur-F5-transduced cells continued to exhibit enhanced tetramer binding (77 and 61%, respectively) as well as a signiWcantly higher MFI than WT-F5 (1,866 and 696, respectively, Fig. 2b ). In six independent experiments, the murinized form of the receptor exhibited a signiWcant increase in the number of tetramer-positive cells in the bulk CD3 + population, as well as, the CD4 + and CD8 + subpopulations (p · 0.05 for all pairs, Fig. 2c ). The MFI of the Mur-F5 tetramer-positive cells was approximately twofold higher than the MFI of the WT-F5 transduced PBL (Fig. 2d) . The MFI of the tetramer-positive Mur-F5-transduced PBL for the CD3 + , CD4 + and CD8 + T cell populations following S1 or R2 was signiWcantly higher than the corresponding WT-F5 groups (Fig. 2d , p · 0.001). The enhanced tetramer binding and the higher MFI of the cells expressing the hybrid receptor were not patient-speciWc phenomena and were seen in at least nine diVerent patients' PBL in six independent experiments. Interestingly, while the CD3 MFI was signiWcantly higher in the F5 S1 cells (p = 0.04), there was no diVerence in CD3 expression between the Mur-F5 and F5 TCR-transduced PBL following a REP (Fig. 2e) .
A murine-human hybrid MART-1 speciWc TCR enhanced antitumor activity following a rapid expansion TCR-transduced PBL expressing WT-F5 or Mur-F5 were maintained in culture for 7-9 days before being placed into a REP. S1 and R2 cells were sampled and tested in the same assay for each group of patients. In a representative experiment, no signiWcant functional diVerences were observed between the two receptors in S1 cells tested on day 8, however, signiWcantly more IFN was released by R2 cells expressing the murinized receptor tested 7 days after the REP (Fig. 3a) . There was substantial patient-to-patient variability within both the S1 and R2 groups; however, the R2 Mur-F5 cells consistently released an average of twofold more IFN when compared with S1 cells assayed at the same time from the same patient (Fig. 3b) . The WT-F5 and Mur-F5 transduced cells were also analyzed for antigen-speciWc cytolytic function. TCR-transduced PBL were able to speciWcally lyse HLA-A2 + / MART-1 + targets (Fig. 3c ), but did not lyse HLA-A2 ¡ targets (Fig. 3d) ; however no signiWcant diVerences were observed between the WT-F5 and Mur-F5 TCR-transduced PBL following S1 or R2. In addition, no signiWcant diVerences in IL-2 secretion were observed between the WT-F5 and Mur-F5 TCR-transduced PBL following S1 or R2 (data not shown).
T cell diVerentiation markers on WT-and Mur-F5 transduced T cells
In an eVort to determine if the diVerentiation state of the T lymphocyte can aVect TCR expression or downstream cell function, phenotypic analysis was performed to look for diVerential expression of known markers of cell diVerentiation. We examined both S1 and R2 WT-and Mur-F5 TCRtransduced PBL, respectively. The phenotypic analysis was based on nomenclature adopted by Foster and others who deWned the major diVerentiation subsets on the basis of CD45RA and CD62L expression with double positives identiWed as naïve cells [25] [26] [27] .
PBL transduced with either the WT-F5 or the Mur-F5 TCR gated on CD3 + /MART-1 tetramer + cells showed similar surface marker expression with a large naïve-like population of CD45RA + /CD62L + T cells after the initial stimulation (S1, Fig. 4a ). Both TCR also yielded similar levels of central memory-like (CD45RA ¡ /CD62L + ) and eVector memory-like (CD45RA ¡ /CD62L ¡ ) T cells. As described earlier, diVerences in receptor expression and eVector function were not seen until after a REP (Figs. 2, 3) . Following a REP, the naïve-like population in both the WT-F5 and Mur-F5 TCR-transduced PBL, was no longer present (Fig. 4b ). In addition, there appears to be a greater proportion of central memory-like cells (CD45RA ¡ / CD62L + ) in the Mur-F5 TCR-transduced cells following a REP (37.5 and 17.5%, respectively).
Vector modiWcations to the Mur-F5 did not further enhance TCR expression or function
Given the increased function of R2 cells transduced with the Mur-F5 TCR, we explored the use of additional vector modiWcations to further enhance the tetramer binding and, more importantly, eVector function of the TCR-transduced PBL. Using previously described techniques [16-18, 28, 29] , the Mur-F5 TCR was modiWed to promote a second disulWde bond between the constant regions of the and chains. In addition, an optimized intrachain linker sequence consisting of a furin cleavage site followed by an SGSG spacer and a P2A linker (furin SGSGP2A) was inserted into the original Mur-F5 and into the cysteine-modiWed Mur-F5 (Fig. 5a) [23] . The addition of a second disulWde bond alone or in combination with the optimized linker sequence resulted in slightly higher levels of tetramer binding as compared to Mur-F5 (Fig. 5b) . However, the data demonstrated that neither the formation of a second disulWde bond in the constant region of the modiWed TCR nor the linker optimization provided any signiWcant functional beneWt as all TCR-transduced cell populations secreted similar levels of IFN (Fig. 5c ).
Discussion
We have described previously, eVorts to improve the pairing and subsequent function of a MART-1 reactive TCR by the creation of a murine-hybrid TCR, as well as, the addition of a second disulWde bond within the constant region of the TCR [15, 16] . While most of the initial studies introduced TCR and chains via RNA electroporation, we sought to evaluate two MART-1-speciWc TCR (WT-F5 and Mur-F5) that share the same variable region sequences and diVer only in the constant regions of the TCR, using clinical grade retroviral vectors of equivalent titers in a clinical transduction protocol. This approach generates highly transduced PBL which enables us to compare TCR expression and function without the need for multiple rounds of in vitro stimulation. A signiWcant increase in both TCR expression, based on MFI, and tetramer binding was observed in both the Mur-F5 S1 and R2 cell populations (Fig. 2) . In addition, following the REP Mur-F5 TCRtransduced PBL demonstrated signiWcantly improved function as measured by IFN release (Fig. 3) . There was no increase in the CD3 MFI following the REP indicating that the overall level of TCR expression was the same for both the WT-F5 and Mur-F5 TCR-transduced PBL. Because the WT-F5 and Mur-F5 TCR have identical variable region sequences, this data suggests that the enhanced tetramer binding and function following the REP in the Mur-F5 transduced cells is likely due to the addition of the murine constant region resulting in improved pairing between the TCR and chains and increased levels of MART-1-reactive TCR on the cell surface. In contrast, previous reports [17] have shown no functional diVerences in longterm cultures of genetically modiWed T cells when expressing comparable levels of TCR; however, the PBL in those experiments had experienced at least six rounds of peptide stimulation to achieve TCR levels comparable to the levels of WT-F5 and Mur-F5 TCR expression in transduced PBL following a single stimulation. In addition, the level of tetramer-positive cells in those experiments was drastically reduced compared to the levels we have seen following transduction with WT-F5 and Mur-F5 both after a single stimulation and a REP. However, only the modiWed TCR in those experiments bound signiWcant amounts of tetramer following in vitro peptide stimulation suggesting that the TCR modiWcations improved pairing and exogenous TCR Effector:Target Ratio % Lysis mel938+ c expression on the cell surface. It is possible that TCR modiWcations aVect each TCR diVerently and in the case of modiWed WT-1 TCRs, the beneWts of improved pairing are only observed when the level of TCR is limiting. In the case of the MART-1 reactive TCR, it has recently been shown that both partial and fully murinized TCR are less likely to form mixed dimmers in the presence of an endogenous human TCR [19] . Thus, the preferential pairing associated with the murine constant region sequences would prevent the dilution of the antigen-speciWc endogenous TCR on the cell surface capable of binding tetramer, as well as, mediating the enhanced antitumor activity.
In a recent review, Gattinoni et al. [30] described a model for linear diVerentiation/activation of T cells. It is unknown whether the introduction of an exogenous murine-human chimeric TCR would have an eVect on T cell diVerentiation in a T cell already expressing an endogenous TCR. In this model, as T lymphocytes diVerentiate from naïve-like to eVector cells, they acquire a greater capacity to release IFN during an antigen-speciWc response, which might account for the enhanced antitumor activity of the Mur-F5 TCR following a REP. Our data suggest that expression of an exogenous high avidity TCR, either WT-F5 or Mur-F5, did not adversely aVect the ability of a T cell expressing an endogenous receptor to become activated and diVerentiate into eVector T cells (Fig. 4) . However, because the overall TCR expression did not change between S1 and R2 cells (Fig. 2) , diVerentiation into a more eVector-like cell cannot alone account for the enhanced tetramer binding and expression of the Mur-F5 TCR on the cell surface. In fact, even though the WT-F5 TCR-transduced PBL exhibited higher levels of eVectormemory T cells following a REP, functionally they produced less IFN when stimulated with the appropriate HLA-restricted tumor antigen-positive targets. As mentioned previously, the highest objective response rates for the treatment of patients with melanoma are observed following TIL ACT. Interestingly, the diVerentiation phenotype of TIL, similar to an R2 cell, is CD45RA ¡ /CD62L ¡ or that of an eVector T cell. In contrast, recent mouse data would suggest that less diVerentiated cells (more similar to S1 cells) would be more eVective at mediating tumor TT TN TEM TCM regression and cures in mice [3, 31] . Clearly more studies will be required to determine which T cell subpopulation is optimal for successful ACT immunotherapy using genetically modiWed PBL.
In an eVort to further enhance TCR pairing and improve function, modiWcations to the Mur-F5 TCR were made including addition of a second disulWde bond within the constant region of the TCR and use of an optimized 2A linker sequence (Fig. 5) . All the constructs showed enhanced tetramer binding when compared with the original Mur-F5 TCR most likely as a result of enhanced TCR cell surface expression due to improved pairing. However, increased tetramer binding did not correlate with enhanced function as measured by cytokine release. These results suggest that while TCR modiWcations may enhance tetramer binding, when the level of tetramer binding is high, possibly approaching saturation, any added functional beneWt may not be easily observed. Taken together, we have shown that replacing the human constant region of a TCR with its murine counterpart can lead to enhanced tetramer binding and function of TCR-transduced PBL following a REP. It would appear that genetic modiWcations to the constant regions of human TCRs will need to be evaluated independently for each TCR being developed, particularly in the case of low avidity TCRs where the added functional beneWts may be more pronounced. In addition, one can now minimize the degree of murine sequence necessary to reduce the formation of mixed dimmers while maintaining the preferential pairing of an exogenous TCR. EVorts are underway to determine additional genetic modiWcations that could further enhance T cell function in bulk PBL and speciWc T cell subsets that might mediate improved tumor regressions in vivo. 
